Plenty of news regarding COVID-19 vaccines this week: on the one hand, today EMA announced that the Committee for Medicinal Products for Human Use (CHMP) has started a rolling review of Sputnik V (Gam-COVID-VAC) COVID-19 Vaccine. On the other hand, EMA also notified that the CHMP will hold an extraordinary meeting on the 11th of March in order to conclude the evaluation of the COVID-19 vaccine developed by Janssen-Cilag International N.V. If there is a positive outcome to this meeting, the evaluation process (which started with a rolling review on December 2020 and was followed by the conditional marketing authorisation evaluation on mid-February 2021) would be completed. If this vaccine is authorized, a total of 4 vaccines will be available on the European market, with three more on the way, already under EMA’s evaluation.
Asphalion is actively aiding in the development of new medicines to treat or prevent COVID-19. With each announcement of the authorization of new treatments and the hope they bring with them, we are sure that this development projects are worth each ounce of the invested effort.
For further information you can contact us at: info@asphalion.com
